


**Listing of Claims****In the claims:**

Please cancel claims 1 and 2, without prejudice, and amend claims 3-11 as follows:

1. **(Canceled)**

2. **(Canceled)**

3. **(Currently Amended)** The An anti-inflammatory compound of claim 1, wherein ~~X<sub>a</sub>~~ consists of comprising the following structure:



wherein

~~n and m are each, independently, 0 or 1;~~

~~A and Y each comprises from 1 to about 3 amino acid residues;~~

X<sub>a</sub> is a membrane translocation domain comprising from 6 to 15 amino acid residues;

X<sub>1</sub> is L, A, I or nor-leucine (Nle);

X<sub>2</sub> is D, E, N, Q, homoserine (Hser) or 2-ketopropylalanine (2-ketopropyl-A);

X<sub>3</sub> is W, F Y, 4-biphenyl-alanine (Bpa), homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), or cyclohexyl-alanine (Cha);

X<sub>4</sub> is S, A, E, L, T, nor-leucine (Nle), or homoserine (Hser);

X<sub>5</sub> is W, H, homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), O-benzyl serine (SeroBn), or 3-Pyridylalanine (3-Pal); and

X<sub>6</sub> is L, A, I, or nor-leucine (Nle).

4. **(Currently Amended)** The anti-inflammatory compound of claim 1, wherein ~~n~~ is 1 and ~~Y is the sequence~~ further comprising the amino acid sequence TA.

5. **(Currently Amended)** The anti-inflammatory compound of claim 1, wherein ~~m~~ is 1 and ~~A is the sequence~~ further comprising the amino acid sequence QTE.

6. **(Currently Amended)** The anti-inflammatory compound of claim 1, wherein ~~X<sub>a</sub>~~ is said compound comprises a sequence selected from the group consisting of TALDWSWLQTE; LDWSWLQTE; TALDWSWL; ALDWSWLQTE; LDWSWLQTE; LDWSWL; TALDWSWLQT; TALDWSWLQ; ALDWSWLQT; LDWSWLQ; LDWSWLQT; ADWSWL; LDWSWA; ADWSWA; LDWSWL; LDYSWL; LDWAWL; LDWEWL; TAADWSWLQTE; ADWSWLQTE; TAADWSWL; AADWSWLQTE; ADWSWLQTE; ADWSWL; TAADWSWLQT; TAADWSWLQ; AADWSWLQT;

ADWSWLQ; ADWSWLQT; ALDWSWAQTE; LDWSWAQTE; TALDWSWA;  
ALDWSWAQTE; LDWSWAQTE; LDWSWA; TALDWSWAQT; TALDWSWAQ;  
ALDWSWAQT; LDWSWAQ; LDWSWAQT; TAADWSWAQTE; ADWSWAQTE;  
TAADWSWA; AADWSWAQTE; ADWSWAQTE; ADWSWA; TAADWSWAQT;  
TAADWSWAQ; AADWSWAQT; ADWSWAQ; ADWSWAQT; TALDFSWLQTE;  
LDFS WLQTE; TALDFS WL; ALDFS WLQTE; LDFS WLQTE; LDFS WL; TALDFS WLQT;  
TALDFS WLQ; ALDFS WLQT; LDFS WLQ; LDFS WLQT; TALDYSWLQTE;  
LDYS WLQTE; TALDYS WL; ALDYS WLQTE; LDYS WLQTE; LDYS WL;  
TALDYS WLQT; TALDYS WLQ; ALDYS WLQT; LDYS WLQ; LDYS WLQT;  
TALDWAWLQTE; LDWAWLQTE; TALDWAWL; ALDWAWLQTE; LDWAWLQTE;  
LDWAWL; TALDWAWLQT; TALDWAWLQ; ALDWAWLQT; LDWAWLQ;  
LDWAWLQT; TALDWEWLQTE; LDWEWLQTE; TALDWEWL; ALDWEWLQTE;  
LDWEWLQTE; LDWEWL; TALDWEWLQT; TALDWEWLQ; ALDWEWLQT;  
LDWEWLQ; and LDWEWLQT.

7. **(Currently Amended)** The anti-inflammatory compound of claim 1 3, wherein X<sub>a</sub> consists of 6-12 amino acid residues.

8. **(Currently Amended)** The anti-inflammatory compound of claim ~~1~~ 3, wherein X<sub>a</sub> consists of 6-10 amino acid residues.

9. **(Currently Amended)** The anti-inflammatory compound of claim 1, wherein X<sub>a</sub> comprises at least five basic amino acid residues.

10. **(Currently Amended)** The anti-inflammatory compound of claim + 7, wherein X<sub>a</sub> comprises at least five amino acid residues independently selected from L-arginine, D-arginine, L-lysine and D-lysine.

11. **(Currently Amended)** The anti-inflammatory compound of claim 4, wherein  $X_a$  is selected from the group consisting of RRMKWKK; YGRKKRRQRRR; ygrkrrqr; YARKARRQARR; yarkarrqarr; YARAARRAARR; yaraarraarr; rrmkwkk, RRRRRR, RRRRRRR, RRRRRRRR, RRRRRRRRR, RRRRRRRRRR, . RRRRR, RRRRRR, RRRRRRR, RRRRRRRR, RRRRRRRRR, and RRRRRRRRRR.

12. **(Original)** An anti-inflammatory compound comprising an amino acid sequence selected from the group consisting of: RRMKWKKTALDWSWLQTE; rrmkwkkTALDWSWLQTE; YGRKKRRQRRRTALDWSWLQTE; ygrkkrrqrrrTALDWSWLQTE; rrrrrrrTALDWSWLQTE; RRRRRRRTALDWSWLQTE; YARKARRQARRTALDWSWLQTE; yarkarrqarrTALDWSWLQTE; YARAARRAARRTALDWSWLQTE; yaraarraarrTALDWSWLQTE

YGRKKRRQRRRLDWSWL; ygrkkrrqrrrLDWSWL; RRMKWKKLDWSWL;  
rrmkwkkLDWSWL; rrrrrrrLDWSWL; YARAARRAARRLDWSWL; yaraarraarrLDWSWL;  
and RRRRRRRLDWSWL.

13. **(Original)** An anti-inflammatory compound having a structure selected from the group consisting of:

H-RRMKWKKTALDWSWLQTE-NH<sub>2</sub>;

H-YGRKKRRQRRRTALDWSWLQTE-NH<sub>2</sub>;

H-rrrrrrrTALDWSWLQTE-NH<sub>2</sub>;

H-YARKARRQARRTALDWSWLQTE-NH<sub>2</sub>;

H-YARAARRAARRTALDWSWLQTE-NH<sub>2</sub>;

H-RRMKWKKLDWSWL-NH<sub>2</sub>;

H-rrmkwkkLDWSWL-NH<sub>2</sub>;

H-rrrrrrrLDWSWL-NH<sub>2</sub>;

H-YARAARRAARRLDWSWL-NH<sub>2</sub>;

H-yaraarraarrLDWSWL-NH<sub>2</sub>; and

H-YGRKKRRQRRRLDWSWL- NH<sub>2</sub>.